The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Clinical trial NCT04984369 · UNKNOWN
Trial details
- NCT number
- NCT04984369
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-11
- Primary completion
- 2024-06-15
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.